Induced Hypoxia and Screening for Cardioprotection
Myocardial ischemia is a pathological condition characterized by a reduced oxygen supply that can lead to cellular apoptosis/necrosis, arrhythmia, organ injury, and even death. Ironically, returning hypoxic myocardium to normoxic levels exacerbates the pathology, collectively known as myocardial reperfusion injury. A primary cause of myocardial ischemia is coronary artery block, and while conventional therapies are in place to minimize cellular damage caused by the hypoxic condition, morbidity and mortality remain high and additional therapeutic approaches for cardioprotection are in demand1.
iCell® Cardiomyocytes provide an ideal preparation for investigating hypoxia and discovering novel potential therapeutic interventions. These human cardiomyocytes are amenable to hypoxia induction (Figure 1), quantification of cellular endpoints (Figure 2), and screening for cardioprotective molecules and/or conditions (Figure 3).
Additionally, iCell Cardiomyocytes can be induced to exhibit hypertrophic and diabetic cardiomyopathies, thus making simultaneous investigation of common ischemia co-morbidities a possibility.
Contact CDI’s Technical Support for additional information on implementing these protocols and more into your research.
- Eltzchig HK, Bonney SK, and Eckle T (2013) Attenuating Myocardial Ischemia by Targeting A2B Adenosine Receptors, Trends Mol Med 19(6):345-54.
- Carlson C, Koonce C, et al. (2013) Phenotypic Screening with Human iPS Cell-derived Cardiomyocytes: HTS-compatible Assays for Interrogating Cardiac Hypertrophy, J Biomol Screen 18(10):1203-11.
- Drawnel FM, Boccardo S, et al. (2014) Disease Modeling and Phenotypic Drug Screening for Diabetic Cardiomyopathy Using Human Induced Pluripotent Stem Cells, Cell Reports 9(3):810-820.